Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?

Canadian Journal of Gastroenterology

Volumn 22, Issue 4, 2008, Pages 357-358

  Chetty, Runjan ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Carcinoid; Neuroendocrine; WHO classification

Indexed keywords

ARTICLE; CANCER GRADING; CANCER STAGING; CARCINOID; DISEASE CLASSIFICATION; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; MEDICAL LITERATURE; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; SMALL CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION;

EID: 44649126776     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/270905     Document Type: Article

References (11)

1. Modlin IM, Shapiro MD, Kidd M. Siegfried Oberndorfer. Origins and perspectives of carcinoid tumors. Hum Pathol 2004;35:1440-51.
2. Creutzfeldt W. Historical background and natural history of carcinoids. Digestion 1994;55(Suppl 3):3-10.
3. Solcia E, Kloppel G, Sobin LH, et al. Histological Typing of Endocrine Tumours (World Health Organization. International Classification of Turnouts), 2nd edn. Heidelberg: Springer-Verlag, 2000.
4. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
5. Artale S, Giannetta L, Cerea G, et al. Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Res 2005;25:4463-9. (Erratum in 2006;26:2187).
6. Bajetta E, Catena L, Procopio G, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 2005;16:1374-80.
7. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006;17:461-6.
8. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12:1083-92.
9. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004;80:244-51.
10. Rindi G, Klöppel G, Alhman H, et al; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
11. Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2007;451:757-62.